Volume 27, Number 1—January 2021
Research
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
Table 2
Clinical characteristic | 2009–2011 |
2015–2017 |
2015–2017 vs. 2009–2011 |
||||||
---|---|---|---|---|---|---|---|---|---|
VT20–13, % | NVT20, % | VT20–13/NVT20 ratio (95% CI) | VT20–13, % | NVT20, % | VT20–13/NVT20 ratio (95% CI) | VT20–13/NVT20 ratio (95% CI) | |||
Carriage in healthy children | NA | NA | NA | 24 | 66 | 0.37 (0.33–0.41) | NA | ||
Carriage in non-LRTI | 18 | 38 | 0.46 (0.38–0.56) | 23 | 66 | 0.35 (0.30–0.40) | 0.80 (0.65–0.98) | ||
Conjunctivitis | 20 | 34 | 0.60 (0.39–0.91) | 19 | 72 | 0.26 (0.17–0.40) | 0.57 (0.35–0.94) | ||
Carriage in LRTI | 13 | 34 | 0.39 (0.30–0.50) | 32 | 57 | 0.56 (0.48–0.65) | 1.26 (1.00–1.60) | ||
OM | 14 | 21 | 0.68 (0.49–0.94) | 34 | 52 | 0.60 (0.44–0.81) | 0.91 (0.66–1.25) | ||
IPD | 15 | 13 | 1.19 (0.79–1.80) | 52 | 38 | 1.40 (1.12–1.73) | 1.05 (0.84–1.31) |
*No data were available for healthy children in 2009–2011. IPD, invasive pneumococcal disease; LRTI, lower respiratory tract infection; NA, not applicable; NVT20, serotypes not included in PCV20; OM, otitis media; PCV, pneumococcal conjugate vaccine; VT20–13, additional 20-valent PCV (PCV20) serotypes, not included in PCV13.
Page created: November 19, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.